NCT03512535

Brief Summary

Plasma redox status is well known to alter with age but previously differences have only been reported for two specific redox couples; reduced and oxidized cysteine and reduced and oxidized glutathione. (Jones DP, Rejuvenation Res. 2006) The overall aim of this project is to develop new methods to determine how other Reactive Nitrogen and Sulfur species, such as free and protein-bound thiols (organic compounds that contain a Sulfhydryl group, -SH) and Hydrogen Sulfide (H2S) change with age and gender in a medium-sized cohort of healthy individuals (n=100 of either sex; age 18-70). Our group has recently developed a novel analytical platform to measure thiol-containing compounds in biological samples that is based on the reaction with the thiol-alkylating agent N-ethylmaleimide (NEM). We have used this chemical for years as stabilisation agent in other analyses to quantify Nitric Oxide metabolites.(Feelisch et al, FASEB 2002 and Levett et al, Sci Rep 2011) We now wish to develop a similar method to measure thiol containing compounds using a novel rapid LC-MS/MS based technology for screening large numbers of individuals. The project will therefore have 2 stages:

  1. 1.Initial method development will require occasional use of whole blood, plasma and red blood cells to establishing optimal conditions. E.g. to compare heparin and EDTA as anticoagulants to serum; investigate effects of temperature and pH; identify optimal concentration of derivatisation/reduction agents and optimal reaction times.
  2. 2.We then aim to establish the normal distribution of these novel compounds across healthy individuals of different gender and varying ages.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
220

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 29, 2018

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

April 18, 2018

Completed
12 days until next milestone

First Posted

Study publicly available on registry

April 30, 2018

Completed
6.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2024

Completed
Last Updated

March 24, 2021

Status Verified

March 1, 2021

Enrollment Period

6.8 years

First QC Date

April 18, 2018

Last Update Submit

March 19, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Concentration of reactive (nitrogen or sulfur containing) species

    Baseline

Study Arms (2)

Stage 1

Samples from up to 20 participants will be used to finalise the analytical methods

Stage 2

Samples from up to 200 participants will be used to then validate the normal ranges of these markers across different age ranges in both genders

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Healthy adult volunteers

You may qualify if:

  • Aged 18 years or above
  • Currently healthy (i.e. no inter-current illness/infection)
  • Capacity and ability to give written informed consent

You may not qualify if:

  • Current or previous smoker
  • Other medical co-morbidity (e.g. hypertension, diabetes, asthma, COPD, cardiovascular disease, current or previous malignant disease etc.)
  • Surgery within previous 28 days
  • Excessive alcohol intake (i.e above UK's recommended intake limit of 14 units per week).
  • Pregnant or currently breast-feeding
  • On current medication
  • Taken vitamins / minerals / herbal remedies within previous 28 days
  • Difficult venous access
  • Needle phobia
  • Participating in another similar/conflicting research study already

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Southampton

Southampton, Hampshire, SO16 6YD, United Kingdom

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Plasma, serum and whole blood pellets

Study Officials

  • Martin Feelisch, PhD

    University of Southampton

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 18, 2018

First Posted

April 30, 2018

Study Start

January 29, 2018

Primary Completion

November 1, 2024

Study Completion

November 1, 2024

Last Updated

March 24, 2021

Record last verified: 2021-03

Locations